Overview

Altreno for Chest Rejuvenation

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This is a single-center, prospective, double-blind, randomized, vehicle-controlled study to evaluate the efficacy, safety and patient satisfaction of tretinoin 0.05% lotion (Altreno) for chest rejuvenation.

Phase:

Phase 4

Details

Lead Sponsor:

Goldman, Butterwick, Fitzpatrick and Groff

Collaborator:

Bausch Health Americas, Inc.

Treatments:

Tretinoin